Vireo Growth Inc.
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$773.5M
Cash Runway
10.4 mo
Lead Asset
—
Next Catalyst
—
Go deeper on Vireo Growth Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on VREOF — live, with citations.
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
10.4 months
D/E 2.16
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of March 31, 2026
Cash
$137.8M
Quarterly Burn
$50.3M
Revenue
$106.2M
Free Cash Flow
$1.1M
Total Liabilities
$634.7M
Shareholders Equity
$294.1M
Current Ratio
1.20
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Commercialization & Governance
Commercialization
- Launch Markets
- MarylandMinnesotaMissouriNevadaNew YorkUtah
- Commercial Strategy
- The Company utilizes a vertically integrated 'seed-to-sale' model, operating cultivation, production, and retail dispensary business lines, with a focus on customer-centric operations and high-quality, science-focused product offerings.
Governance
- Board Size
- 7
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$4
| Holder | Shares | Value |
|---|---|---|
| resources management corp /ct/ /adv | 10,000 | $4 |
Frequently asked questions
Who is the CEO of Vireo Growth Inc.?
Mr. John Michael Mazarakis is the chief executive officer of Vireo Growth Inc. (VREOF).
Where is Vireo Growth Inc. headquartered?
Vireo Growth Inc. (VREOF) is headquartered in Minneapolis, MN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Vireo Growth Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.